GleamWall
中文EN

NVS NOVARTIS AG IFRS

Pharmaceutical Preparations · NYSE · SEC CIK 1114448 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY8.4%
TTM net income YoY17.1%
TTM EPS YoY21.8%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR26.2%

Margins

Gross margin78.8%
Operating margin32.4%
Net margin25.6%
FCF margin32.3%
EBITDA margin—

Returns

ROE31.0%
ROA13.1%
ROIC (approx.)44.8%
Asset turnover0.51x

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.00x
Current ratio1.12x
Interest coverage15.42x

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio-4.8%
Payout ratio55.9%
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q22025-06-302024Q22024-06-302023Q22023-06-302022Q22022-06-302021Q22021-06-302020Q22020-06-302019Q22019-06-302018Q22018-06-30
Income statement
Revenue$14.05B$12.51B$11.44B$12.78B$12.96B$11.35B$11.76B$11.36B
Cost of revenue$3.32B$3.17B$3.34B$3.75B$3.91B$3.43B$3.41B$3.56B
Gross profit$11.51B$9.70B$8.40B$9.33B$9.38B$8.19B$8.62B$8.10B
R&D expense$2.73B$2.37B$2.30B$2.50B$2.40B$2.44B$2.05B$2.13B
SG&A expense$3.44B$3.09B$3.09B$3.58B$3.75B$3.37B$3.58B$3.50B
Operating income$4.86B$4.01B$2.81B$2.23B$3.48B$2.35B$2.66B$2.43B
Interest expense$289.00M$246.00M$216.00M$202.00M$201.00M$220.00M$205.00M$237.00M
Pretax income$4.53B$3.84B$2.67B$2.04B$3.51B$2.29B$2.63B$8.17B
Income tax$507.00M$595.00M$403.00M$347.00M$611.00M$421.00M$525.00M$443.00M
Net income$4.04B$3.25B$2.32B$1.69B$2.90B$1.87B$6.80B$7.77B
EPS (basic)2.071.601.110.771.290.822.943.34
EPS (diluted)2.061.591.110.771.280.812.913.31
Weighted avg. shares (diluted)1.96B2.05B2.10B2.21B2.26B2.30B2.33B2.35B
Balance sheet
Cash & equivalents$6.66B$7.90B$10.88B$3.62B$5.12B$5.92B$9.99B$12.45B
Receivables$9.06B$8.23B$9.20B$8.64B$8.40B$7.64B$7.97B$8.80B
Inventory$6.31B$5.75B$8.23B$6.88B$7.11B$6.90B$6.09B$7.10B
Current assets$25.94B$25.69B$33.49B$38.14B$23.81B$23.88B$28.32B$32.06B
PP&E, netmay include right-of-use assets (IFRS)$10.38B$9.25B$10.82B$10.73B$11.74B$11.96B$12.29B$15.96B
Goodwill$25.55B$25.23B$29.52B$29.11B$29.77B$29.10B$26.53B$35.17B
Intangibles$29.24B$27.77B$28.00B$33.37B$34.82B$36.67B$27.22B$39.44B
Total assets$104.39B$97.50B$110.98B$122.91B$124.02B$123.76B$116.29B$142.06B
Current liabilities$31.71B$27.61B$31.91B$27.65B$29.63B$29.38B$30.11B$27.94B
Total liabilities$62.34B$55.60B$59.05B$59.90B$69.89B$69.88B$64.79B$65.16B
Shareholders' equity$41.98B$41.73B$51.85B$62.92B$54.04B$53.81B$51.43B$76.81B
Shares outstanding———————2.32B
Cash flow statement
Operating cash flow$6.66B$4.88B$3.58B$3.75B$4.13B$3.96B$3.11B$3.94B
Capital expenditure$331.00M$260.00M$225.00M$257.00M$321.00M$238.00M$279.00M$257.00M
Free cash flow$6.33B$4.62B$3.35B$3.50B$3.81B$3.72B$2.83B$3.69B
Investing cash flow-$2.24B-$3.21B-$1.05B-$11.63B$97.00M-$425.00M-$474.00M$4.33B
Financing cash flow-$5.21B-$3.20B-$3.64B-$2.30B-$2.94B-$2.19B-$28.00M-$1.53B
Stock-based compensation$267.00M$257.00M$222.00M$204.00M$185.00M$199.00M$174.00M$155.00M
Dividends paid$2.48B$2.42B——————
Share buybacks$2.71B$1.62B$2.96B$2.71B$703.00M$9.00M$2.37B$599.00M

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.